Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused ...

For the seventh consecutive year, the Top Employer Institute has recognized Boehringer Ingelheim as a Top Employer in the ...

经济观察网讯 2月24日，勃林格殷格翰（Boehringer Ingelheim）宣布，其在研肺纤维化疗法 口服磷酸二酯酶4B（PDE4B）抑制剂那米司特片（nerandomilast） 的上市申请已获得中国国家药监局药品审评中心（CDE）受理， ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

此外，在2024年世界肺癌大会上发表的数据还显示，zongertinib具有初步的脑活性。根据盲法独立中央审评（BICR）的评估，33%（120 mg，n=27）和40%（240 ...

Boehringer Ingelheim, the Germany-based research-driven biopharmaceutical company, has signed a Memorandum of Understanding (MoU) with Kenya's Mission for Essential Drugs and Supplies (MEDS) to expand ...

此外，早前在2024年世界肺癌大会上发布的结果显示，zongertinib展现出显著的脑部活性。对于无症状脑转移的患者，在不同剂量下分别有33%（120mg）和40%（240mg）患者达成确认的客观缓解，疾病控制率高达74%和92%。值得一提的是，NSCLC患者常常出现脑转移，这与生存预后和生活质量密切相关，因此这一发现无疑是一次重大突破。

An Illinois jury ruled in favor of Boehringer Ingelheim in Zantac litigation brought by two prostate cancer patients, the ...

Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...